PARP1 inhibitors in breast cancer therapy. Mechanism of action and clinical use
It is known that currently PARP inhibitors are actively used in the treatment of tumors of the female reproductive system. A large number of studies have been presented demonstrating the effectiveness of PARP inhibitors in the treatment of BRCA-associated ovarian cancer. It was found that mutations...
Saved in:
Main Authors: | D. S. Dolgasheva (Author), A. M. Pevzner (Author), M. K. Ibragimova (Author), N. V. Litvyakov (Author), M. M. Tsyganov (Author) |
---|---|
Format: | Book |
Published: |
ABV-press,
2020-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advances in the use of PARP inhibitor therapy for breast cancer
by: Kelly E McCann, et al.
Published: (2018) -
PARP inhibitor resistance in breast and gynecological cancer: Resistance mechanisms and combination therapy strategies
by: Nannan Wang, et al.
Published: (2022) -
Resistance to PARP-inhibitors in Cancer Therapy
by: Alicia eMontoni, et al.
Published: (2013) -
DNA Copy Number Aberrations and Expression of ABC Transporter Genes in Breast Tumour: Correlation with the Effect of Neoadjuvant Chemotherapy and Prognosis of the Disease
by: Matvey M. Tsyganov, et al.
Published: (2022) -
Integration of PARP-inhibitors in ovarian cancer therapy
by: Antonella Pietragalla, et al.
Published: (2020)